Dr. Haidry has is actively involved in several research projects at world leading University College London and continues to be published in several leading journals in his field. He says, “I am fully committed to high quality clinical research to provide innovative and state of the art care to our patients. This is why I am involved in several important clinical trials and why I continue to push the boundaries of research excellence through my role as Honorary Associate Professor at University College London”.
His research interests are focused on developing new methods for detecting and treating dysplasia (early cancer) in Barrett’s Oesophagus and other pathologies of the gastrointestinal tract. He coordinates and runs one of Europe’s largest endoscopy registries, the UK Radiofrequency ablation registry, which collects nationwide outcomes of this exciting new intervention in patients with early cancer of the oesophagus. He explains “The outlook for patients with oesophageal cancer is poor in our country due to the fact that we often diagnose them late. By diagnosing patients with reflux and Barrett’s Oesophagus early we are now successfully treating many patients with early oesophageal cancer and really making a difference.”
He is currently looking at new procedures such as cryoablation for freezing away early cancers of the oeosphagus – this appears to be an exciting technology for the future. He was the first to perform cryo-ablation for patients with Barrett’s oeosphagus and early squamous cancer in the UK and is currently leading on a large European study examining this technique in patients.
He is also exploring endoscopic approaches to treat patients with Type 2 Diabetes Mellitus which affect over 3 million people in the United Kingdom. Duodenal mucosal resurfacing (DMR) is an innovative and novel endoscopic intervention for the treatment of patients with poorly controlled Type 2 DM. The first ever cases in the UK have been carried out by Dr. Rehan Haidry at UCLH in the 2015. Carefully selected patients with Type 2 DM have undergone successful treatment as part of a multi-center study (Amsterdam, Brussels, Rome) with 12 month follow up showing improvements in glycemic control in all patients treated to date. He has recently published these findings in Gastro Intestinal Endoscopy in 2019 and will be offering this to patients at the London Clinic in the coming months.
This new technique was recently reviewed in the Wall street Journal and Daily mail – click on the link to learn more and see video interview with Dr Haidry.
In 2020 Dr Haidry will be initiating a state of the art trial and international prospective registry looking at a new intervention called cryoablation for the treatment of patients with early oesophageal cancer. The procedure was pioneered in the USA and has been used in over 100 patients in Johns Hopkins Hospital. The technique uses the concept the freezing the abnormal cells in the superficial layers of the oeosophagus to destroy them and has shown some very promising results in the early studies.
Small Intestinal Bacterial overgrowth
Dr Haidry sees many patients with a common and poorly understood condition called Small Intestinal Bacterial overgrowth – here he writes short overview of how he approaches these patients that he sees in his clinic quite often
OVERVIEW OF DIAGNOSIS AND MANAGEMENT OF SMALL INTESTINAL BACTERIAL OVERGROWTH – “My tips to tackle a common problem”
by Dr Rehan Haidry
SIBO (small intestinal bacterial overgrowth) is a relapsing and remitting condition that affects up to 10-15% of the general population. The hallmark of SIBO is that the small intestine becomes colonised with normal occurring gut flora. The small intestine is normally devoid of any bacterial colonisation but changes in the environment within the small bowel can lead to overgrowth of bacteria which can manifest with a myriad of symptoms which are the hallmark of SIBO.
Once a patient develops SIBO they can present with a constellation of symptoms including bloating, abdominal discomfort, gas, diarrhoea and fatigue, amongst many others. For many years’ patients with SIBO symptoms have been diagnosed and labelled with irritable bowel syndrome. This is predominantly because there is a lack of consensus and clarity internationally regarding the natural history of the disease, the best modality for diagnosing it but also a lack of robust data on the optimum treatment algorithm for these patients.
The small intestine does not normally have any bacterial colonisation. In SIBO what happens is that bacteria that normally live within the gastrointestinal tract, predominantly in our large bowel, start to grow within the small bowel. As a result, these bacteria feed off small molecules like fermentable carbohydrates and sugars that we ingest. These are present in almost everything that we eat and the subsequent gas production in SIBO can cause problems with digestion, absorption of food and damaging the membranes in the lining of the small intestine leading to all of the above symptoms.
The diagnosis of bacterial overgrowth still remains an area of controversy with several different modalities being proposed. At The London Gastroenterology Centre we offer a simple and non-invasive way of testing for it by using a simple breath test. Please contact my team if you would like to arrange a test. It must be noted that there is not a universally-acceptable gold standard test for SIBO and the use of the lactulose breath test has become extremely common over the past five years. The purpose of this test is to try and replicate an environment within the small bowel that would occur on a day-to-day basis in patients with small intestinal bacterial overgrowth and then measure the production of gasses that are resultantly produced in the small bowel to quantify whether there is indeed SIBO. Quantification of hydrogen and methane gas in breath samples is the most inexpensive, non-invasive and probably the most widely available test for a diagnosis of bacterial overgrowth within the United Kingdom. When we measure these gasses in human breath, it signifies the metabolism of fermentable carbohydrates that reside in the small bowel. It is also very important to gauge the success of any intervention for the treatment of bacterial overgrowth by repeating a breath test weeks later to ensure that there has been not just a resolution in the production of hydrogen and methane following either antibiotics or dietary restriction, but also to understand that the patient’s symptoms have responded. Certainly, in my practice I almost always repeat the breath test six weeks after any intervention to ensure that there has been success.
Interestingly once patients have completed the breath tests, I often sit with them and discuss the likelihood of the long-term durability of successful treatment but also a number of courses of antibiotics that patients are likely to require to eradicate the SIBBO. It must be noted that not every patient needs antibiotics, and as you will read later on in this article other modalities can be explored in my practice. From my experience for the average person each course of two weeks of antibiotics results in an average drop of 25-35ppm in gas production. It would be noted, however, that some people will experience far greater decreases. Normal gas production in the small intestine in the first 120 minutes of the breath test should be less than 20ppm of hydrogen and less than 12ppm of methane, therefore based on the lactulose breath test that you have at The London Gastroenterology Centre and the magnitude of the gas production we can estimate how many rounds of treatment you are likely to require.
Treatment of SIBO in my practice comprises three strategies. Firstly, is to induce remission of SIBO, secondly is to try and maintain remission and prevent SIBO returning and finally and probably as importantly is to treat or modify the underlying cause or predisposing factors that are leading to the development of SIBO.
The treatment of bacterial overgrowth, although controversial, is still predominantly focussed on trying to decrease the numbers and overgrowth of bacteria in the small bowel and antibiotics remain the mainstay of therapy for now. It must be stated, however, that the choice, dose and duration of antibiotic therapy are still not fully understood as there have been very limited high-quality studies that guide clinicians on which antibiotic to use.
However, certainly in my practice over the past five years I have focussed on using Rifaximin, which is one of the most extensively-studied antibiotics in patients with all types of functional bowel disorders. It has some excellent studies from around the world showing it is safe and effective for treating SIBIO. It is particularly effective in those with hydrogen over production and diarrhoea and bloating symptoms. The problem in the United Kingdom is that it is only approved for the use of travellers’ diarrhoea but also in patients with liver disease and therefore its use in small intestinal bacterial overgrowth is often problematic, as many hospitals or GP practices will not prescribe it and patients often have to pay for a two week course of antibiotics. Nonetheless there have been many studies that have shown that in patients with bacterial overgrowth and hydrogen overproduction that Rifaximin can be efficacious. Please ask the team at the LGC for more information on how to source Rifaximin in the UK.
It must also be noted that when we carry out breath tests to look for SIBO we also look for methane gas production. There is good evidence that has been presented recently at Digestive Disease Weekly in Chicago 2017, showing that methane overproduction can lead to slow transit and motility of the gut and these patients often do not respond to Rifaximin alone and need a second antibiotic. Neomycin is a safe antibiotic that has been used in various other disease states and has been shown to improve methane overproduction in patients. The use of pro-kinetics in this cohort of patients such as a low dose of a drug called prucalopride can supplement the effect of the antibiotics to stimulate gut motility and enhance the efficacy of the treatment.
In some patients there is also the option of herbal antibiotics and I see a lot of patients at The London Gastroenterology Centre who want to explore this. We are happy to discuss and guide patients as to which herbal antibiotics to use as long as they are sourced from a reputable chemist. The options are however very limited.
Maintenance of remission is very important as SIBO is a relapsing disorder in several patients. In some studies up to one-third of patients will have a relapse of small intestinal bacterial overgrowth and watchful observation is mandatory in patients after induction of remission of SIBO to ensure if there are recurring symptoms that early treatment is instigated. In my practice at The London Gastroenterology Centre I use the following modalities in preventing SIBO from returning and one of the things a patient should look at is firstly diet. Limiting fermentable carbohydrates and following a diet such as the low FODMAP diet can ensure that the luminal environment is exposed to low fermentable foods and can ensure that there is a less favourable environment for any residual bacteria to overgrow. Data have shown that in some patients a low FODMAP diet alone can induce remission in patients with bacterial overgrowth. As importantly the movement and motility of the small bowel needs to be optimised by the use of pro-kinetics. Prokinetics help stimulate the MMC (migrating motor complex) of the small intestine to prevent recurrence and recolonization of bacteria. I always advise patients that as soon as they have finished their first course of antibiotic treatment we can look at prokinetics. Again these fall into herbal options such as iberogast drops which can be taken at night or pharmacological treatments such as a low dose of Resolor (prucalopride) at night. I also encourage patients to explore the use of digestive and pancreatic enzymes in trying to optimise the small bowel environment after treatment to prevent SIBO from returning.
In some patients in whom the above measures have not been successful one can look at using more rigorous dietetic exclusion such as the elemental diet. I have to be honest that this is only reserved for patients with really refractory symptoms despite at least tow to three courses of antibiotics and failure of a trial of a low FODMAP diet. In the simplest description an elemental diet is a diet that consists of a liquid formula that contains pre-digested carbohydrates, proteins and fats and has been used for many years in the treatment of conditions such as Crohn’s disease. What the elemental diet means is that the above nutrients are absorbed very quickly through the digestive system, which is helpful in patients with bacterial overgrowth as we do not want food sitting around in the small intestine where it can be used to fuel gas production for the unwanted overgrowth of bacteria. An elemental diet provides a way to nourish the patient whilst starving off the bacteria. Implementing the elemental diet is almost always done under the supervision of one of our expert dieticians, and the patients will drink a formula instead of their regular meals for up to two to three weeks depending on the severity of their symptoms and their medical background. It must also be emphasised that there is not a plethora of high-quality studies on the use of the elemental diet but there are some studies that have shown that in some patients following 14 days of the elemental diet there is an 80% response with negative breath test after treatment. Clearly there are drawbacks with this and the most important one is that of compliance; it can be extremely difficult to limit one’s dietary intake just to liquids for two weeks. If you would like to discuss the use of the elemental diet, then please contact The London Gastroenterology Centre to make an appointment to discuss further. We can then connect you with one of our dieticians
Finally, there has been a lot of interest in the role of probiotics and prebiotics over the past decade and I often get asked by patients as to whether these have a role in the treatment of bacterial overgrowth. The exact role of probiotics in the management of SIBO remains unclear and needs to be clarified. Certainly, anecdotally it makes sense that by replacing unwanted bacteria with good bacteria so to speak will have a beneficial effect on patients. Nonetheless I do advise caution on the use of probiotics after treatment of bacterial overgrowth as it can in some patients make things slightly worse in the short term.
In summary as you can read in the paragraphs above small intestinal bacterial overgrowth is a common and often stubborn disease to treat. We have moved away from focusing purely on an antibiotic-focussed treatment of these patients and are now able to offer a variety of different interventions that I am happy to discuss with patients in clinic.
If you would like to make an appointment to be tested for SIBO or discuss management of your SIBO then please contact Dr Haidry’s team at The London Gastroenterology Centre on the numbers above.
Dr Haidry is one of the first endoscopists in the United Kingdome to offer this new and innovative treatment at the London Clinic. He spent time in Belgium learning to perform the procedure before working with his Bariatric Colleagues to introduce the procedure to University College Hospital which became the first NHS site to offer this exciting procedure to patients. The London Clinic is now the first private unit in London to offer this procedure. Please arrange an appointment to see Dr Haidry at 116 Harley street if you would like to discuss this procedure further to see if you are eligible.
Here he gives an overview of the procedure and the patients it may help.
Why do we need an alternative to surgery for patients who are overweight in the United Kingdom?
There is a growing need for therapy for patients who are overweight and obese, as in the UK, 27% of adults have been diagnosed with obesity, body mass index of 30 kg/m2 or more. Obesity is associated with increased morbidity and mortality. Weight loss reduces obesity-linked co-morbidities with greater weight loss leading to greater health improvement. Lifestyle interventions are the cornerstone of reducing body weight but rarely lead to more than 3% weight loss. Currently, there are limited drugs available that show significant and sustained weight loss. In contrast bariatric surgery, leads to marked sustained weight loss with improvement in health and improved life expectancy
According to NICE guidance bariatric surgery should be considered as a treatment option for people with a body mass index (BMI) of 40 kg/m2 or more or people with a BMI of 35 kg/m2 or more with an obesity-associated co-morbidity. NICE guidance was updated in 2014 stating that people with type 2 diabetes (T2D) of recent onset (within 10 years) with a BMI of 35 kg/m2 or more should have an expedited referral for consideration for bariatric surgery. In addition, people with a BMI between 30 and 34.9 kg/m2 could also be considered. However, access to surgery is extremely limited with less than 1% of eligible people accessing surgery. These patients exist within the bariatric service at present with limited options other than medical therapy which is not often the solution.
What is this new procedure and how does it work?
In an Endoscopic Sleeve Gastroplasty, the doctors creates a narrow pouch, or sleeve within your stomach, using an endoscope (a camera which passes from your mouth into your stomach. This reduces the size of your stomach with the aim of helping you to lose weight. ESG uses the Apollo Endosurgery OverStitch Device, which allows the endoscopist to perform plications (stitches) along the greater curvature of the stomach, creating a reduction is the volume of the stomach similar to a sleeve gastrectomy seen in surgery.
The procedure involves an upper endoscopy and a subsequent application of sutures to the greater curve of the stomach to reduce the capacity of the stomach. The procedure aims to reduce the size of your stomach by about 70%. This means food stays in your stomach for longer making you feel more full and for longer.
This will be used in patients with obesity who are either unable to undergo bariatric surgery or who would not be willing to do so. The procedure is carried out in endoscopy under full anesthesia by Dr Haidry and his team. All our patients will need to come through a bariatric Multi disciplinary team and be counselled by dieticians and endocrinologists at the London Clinic to ensure we look after all their needs before and after the procedure.
PLEASE INSERT VIDEO OF ESG / NEW VIDEO SENT BY DROPBOX
Here is short animation of the procedure to show who the sutures work in the stomach.
In addition, if you have the procedure you will have special dietary advice given to help you lose weight and reduce risk of problems after the procedure. Below you will find some more detailed information on the potential benefits of the procedure, the procedure itself and the risks and alternatives to the procedure. Please do ask our team if there is anything which is not clear or which you would like more information about.
What are the potential benefits of losing weight for people with obesity?
For people with obesity, losing weight can significantly improve the symptoms of diseases like heart disease, diabetes, high blood pressure and joint and sleep problems. In addition, losing weight can reduce the risk of these diseases happening at a later stage. Having a lower weight can also improve the life expectancy of people with obesity.
People considering these sorts of procedures need to be committed to making permanent changes to their eating habits and lifestyle. The procedure is very much the start of the treatment.
Who is suitable for this procedure?
The decision of the suitability for the procedure has to be made by Dr Haidry and also an experienced team as this may not be suitable for everyone with obesity. At present the ESG is offered to these patients:
- They have a BMI (body mass index) of 40-45kg/m2 – you can find a calculator for this at: https://www.nhs.uk/Tools/Pages/Healthyweightcalculator.aspx
- They have a BMI of 35-45 kg/m2 and a health problem like diabetes or sleep apnoea which would be improved by losing weight
- They have tried to lose weight through other methods over a prolonged period of time without success
- They are aged over 18 years old
- They do not have another medical or psychological condition which makes them unsuitable for the procedure
- They are able to have a general anaesthetic
- They do not smoke
- They are committed to long term follow up and dietary advice
How much weight will I lose with the ESG?
Weight loss after the operation is initially very swift but this will settle down after the first few weeks. It is important not to compare your weight loss with any other patient as it is very individual. There may be some weeks in which your weight loss slows down or stops and this is perfectly normal.
On average, people can lose up to 30% of their excess weight in the first 6 months after having an ESG. Recent data from the USA published in May 2019 show that after 5 years ESG is effective in achieving durable significant total body weight loss of 15%. Maximum weight loss is generally achieved by 24 months after the procedure, after which patients tend to regain a small amount of their lost weight.
Please make an appointment to meet with Dr Haidry If you are interested in ESG.
Dr Haidry’s Research Publications
|2021||The natural history of low-grade dysplasia in Barrett’s esophagus and risk factors for progression.|
|Hussein M, Sehgal V, Sami S et al. JGH open 2021. doi.org/10.1002/jgh3.12625|
|2021||Treating esophageal squamous cell carcinoma with ablation: the fear of what lies beneath.|
|Montgomery EA, Haidry R. Gastrointest Endosc. 2021 Aug 18:S0016-5107(21)01495-4. doi: 10.1016/j.gie.2021.07.006. Online ahead of print.PMID: 34419245|
|2021||Serial ctDNA detection using a personalized, tumor-informed assay in esophageal adenocarcinoma patients following resection.|
|Ococks E, Sharma S, Tian Ng AW, Aleshin A, Fitzgerald RC, Smyth E; OCCAMS Consortium, Fitzgerald RC, Edwards PAW, Grehan N, Nutzinger B, Fidziukiewicz E, Redmond AM, Northrop A, Abbas S, Smyth EC, O’Donovan M, Miremadi A, Malhotra S, Tripathi M, Grantham A, Cheah C, Coles H, Flint C, Eldridge M, Secrier M, Devonshire G, Jammula S, Davies J, Crichton C, Carroll N, Hardwick RH, Safranek P, Hindmarsh A, Sujendran V, Hayes SJ, Ang Y, Sharrocks A, Preston SR, Bagwan I, Save V, Skipworth RJE, Hupp TR, O’Neill JR, Tucker O, Beggs A, Taniere P, Puig S, Contino G, Underwood TJ, Walker RC, Grace BL, Lagergren J, Gossage J, Davies A, Chang F, Mahadeva U, Goh V, Ciccarelli FD, Sanders G, Berrisford R, Chan D, Cheong E, Kumar B, Sreedharan L, Parsons SL, Soomro I, Kaye P, Saunders J, Lovat L, Haidry R, Scott M, Sothi S, Lishman S, Hanna GB, Peters CJ, Moorthy K, Grabowska A, Turkington R, McManus D, Coleman H, Petty RD. Gastroenterology. 2021 Jul 17:S0016-5085(21)03245-5. doi: 10.1053/j.gastro.2021.07.011. Online ahead of print.PMID: 34284036|
|2021||Bariatric and Metabolic Endoscopy: A New Paradigm.|
|Telese A, Sehgal V, Magee CG, Naik S, Alqahtani SA, Lovat LB, Haidry RJ. Clin Transl Gastroenterol. 2021 Jun 18;12(6):e00364. doi: 10.14309/ctg.0000000000000364.PMID: 34142665|
|2021||Hemostatic powder TC-325 treatment of malignancy-related upper gastrointestinal bleeds: International registry outcomes.|
|Hussein M, Alzoubaidi D, O’Donnell M, de la Serna A, Bassett P, Varbobitis I, Hengehold T, Ortiz Fernandez-Sordo J, Rey JW, Hayee B, Despott EJ, Murino A, Graham D, Latorre M, Moreea S, Boger P, Dunn J, Mainie I, Mullady D, Early D, Ragunath K, Anderson J, Bhandari P, Goetz M, Kiesslich R, Coron E, Rodriguez de Santiago E, Gonda T, Gross SA, Lovat LB, Haidry R.J Gastroenterol Hepatol. 2021 Jun 15. doi: 10.1111/jgh.15579. Online ahead of print.PMID: 34132412|
|2021||Successful endoscopic management of a large duodenal arteriovenous malformation using an over-the-scope clip.|
|Laskaratos FM, Sehgal V, Haidry R.Endosc Int Open. 2021 Jun;9(6):E909-E910. doi: 10.1055/a-1399-8589. Epub 2021 May 27.PMID: 34079876|
|2021||Side effects of long-term use of proton pump inhibitors: practical considerations.|
|Castellana C, Pecere S, Furnari M, Telese A, Matteo MV, Haidry R, Eusebi LH.Pol Arch Intern Med. 2021 Jun 29;131(6):541-549. doi: 10.20452/pamw.15997. Epub 2021 May 13.PMID: 33982542|
|2021||Revising the European Society of Gastrointestinal Endoscopy (ESGE) research priorities: a research progress update.|
|Bhandari P, Longcroft-Wheaton G, Libanio D, Pimentel-Nunes P, Albeniz E, Pioche M, Sidhu R, Spada C, Anderloni A, Repici A, Haidry R, Barthet M, Neumann H, Antonelli G, Testoni A, Ponchon T, Siersema PD, Fuccio L, Hassan C, Dinis-Ribeiro M. Endoscopy. 2021 May;53(5):535-554. doi: 10.1055/a-1397-3005. Epub 2021 Apr 1.PMID: 33822332|
|2021||Endoluminal resective therapy for residual esophageal neoplasia after definitive chemoradiotherapy: Who are we helping-the patient or the endoscopist?|
|Haidry R. Gastrointest Endosc. 2021 Apr;93(4):899-901. doi: 10.1016/j.gie.2020.10.002.PMID: 33741090|
|2021||Systematic review with meta-analysis: risk factors for Barrett’s oesophagus in individuals with gastro-oesophageal reflux symptoms.|
|Eusebi LH, Telese A, Cirota GG, Haidry R, Zagari RM, Bazzoli F, Ford AC. Aliment Pharmacol Ther. 2021 May;53(9):968-976. doi: 10.1111/apt.16321. Epub 2021 Mar 11.PMID: 33705573|
|2021||Accuracy of clinical staging for T2N0 oesophageal cancer: systematic review and meta-analysis.|
|Wolfson P, Ho KMA, Bassett P, Haidry R, Olivo A, Lovat L, Sami SS.Dis Esophagus. 2021 Feb 23:doab002. doi: 10.1093/dote/doab002. Online ahead of print.PMID: 33618359|
|2021||Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial.|
|Mingrone G, van Baar AC, Devière J, Hopkins D, Moura E, Cercato C, Rajagopalan H, Lopez-Talavera JC, White K, Bhambhani V, Costamagna G, Haidry R, Grecco E, Galvao Neto M, Aithal G, Repici A, Hayee B, Haji A, Morris AJ, Bisschops R, Chouhan MD, Sakai NS, Bhatt DL, Sanyal AJ, Bergman JJGHM; Investigators of the REVITA-2 Study.Gut. 2021 Feb 17:gutjnl-2020-323608. doi: 10.1136/gutjnl-2020-323608. Online ahead of print.PMID: 33597157|
|2021||Utility and Cost-Effectiveness of a Nonendoscopic Approach to Barrett’s Esophagus Surveillance After Endoscopic Therapy.|
|Eluri S, Paterson A, Lauren BN, O’Donovan M, Bhandari P, di Pietro M, Lee M, Haidry R, Lovat L, Ragunath K, Hur C, Fitzgerald RC, Shaheen NJ.Clin Gastroenterol Hepatol. 2021 Feb 10:S1542-3565(21)00147-6. doi: 10.1016/j.cgh.2021.02.013. Online ahead of print.PMID: 33581357|
|2021||A clinically interpretable convolutional neural network for the real-time prediction of early squamous cell cancer of the esophagus: comparing diagnostic performance with a panel of expert European and Asian endoscopists.|
|Everson MA, Garcia-Peraza-Herrera L, Wang HP, Lee CT, Chung CS, Hsieh PH, Chen CC, Tseng CH, Hsu MH, Vercauteren T, Ourselin S, Kashin S, Bisschops R, Pech O, Lovat L, Wang WL, Haidry RJ.Gastrointest Endosc. 2021 Aug;94(2):273-281. doi: 10.1016/j.gie.2021.01.043. Epub 2021 Feb 5.PMID: 33549586|
|2021||Radiofrequency ablation for Barrett’s oesophagus related neoplasia with the 360 Express catheter: initial experience from the United Kingdom and Ireland-preliminary results.|
|Magee CG, Graham D, Gordon C, Dunn J, Penman I, Willert R, Smart H, Ortiz-Fernandez-Sordo J, Ragunath K, Everson M, Alzoubaidi D, Banks M, Morris D, Sami S, Morris AJ, Bhandari P, Narayanasamy R, Di Pietro M, Lovat LB, Haidry R.Surg Endosc. 2021 Feb 5. doi: 10.1007/s00464-021-08325-0. Online ahead of print.PMID: 33547491|
|2021||The Clinical Relevance of Manometric Esophagogastric Junction Outflow Obstruction Can Be Determined Using Rapid Drink Challenge and Solid Swallows.|
|Sanagapalli S, McGuire J, Leong RW, Patel K, Raeburn A, Abdul-Razakq H, Plumb A, Banks M, Haidry R, Lovat L, Sehgal V, Graham D, Sami SS, Sweis R.Am J Gastroenterol. 2021 Feb 1;116(2):280-288. doi: 10.14309/ajg.0000000000000988.PMID: 33136563|
|2020||Esophageal squamous dysplasia and cancer: Is artificial intelligence our best weapon?|
|Hussein M, Everson M, Haidry R.Best Pract Res Clin Gastroenterol. 2021 Jun-Aug;52-53:101723. doi: 10.1016/j.bpg.2020.101723. Epub 2020 Dec 29.PMID: 34172257|
|2020||Surveillance of patients with Barrett’s esophagus after complete eradication of intestinal metaplasia.|
|Esteban López-Jamar JM, Asokkumar R, Ortiz-Fernández-Sordo J, Haidry RJ.Rev Esp Enferm Dig. 2020 Nov;112(11):864-868. doi: 10.17235/reed.2020.7221/2020.PMID: 33054309|
|2020||Measuring Quality in Barrett’s Esophagus: Time to Embrace Quality Indicators.|
|Sehgal V, Ragunath K, Haidry R. Gastrointest Endosc Clin N Am. 2021 Jan;31(1):219-236. doi: 10.1016/j.giec.2020.09.006. Epub 2020 Oct 24.PMID: 33213797|
|2020||Duodenal mucosal resurfacing: Multicenter experience implementing a minimally invasive endoscopic procedure for treatment of type 2 diabetes mellitus.|
|van Baar ACG, Haidry R, Rodriguez Grunert L, Galvao MPN, Bisschops R, Hayee BH, Costamagna G, Deviere J, Bergman JJGHM. Endosc Int Open. 2020 Nov;8(11):E1683-E1689. doi: 10.1055/a-1244-2283. Epub 2020 Oct 22.PMID: 33140025|
|2020||Role of artificial intelligence in the diagnosis of oesophageal neoplasia: 2020 an endoscopic odyssey.|
|Hussein M, González-Bueno Puyal J, Mountney P, Lovat LB, Haidry R. World J Gastroenterol. 2020 Oct 14;26(38):5784-5796. doi: 10.3748/wjg.v26.i38.5784.PMID: 33132634|
|2020||Endoscopic tumour morphology impacts survival in adenocarcinoma of the oesophagus.|
|Knight WRC, McEwen R, Byrne BE, Habib W, Bott R, Zylstra J, Mahadeva U, Gossage JA; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium. Eur J Surg Oncol. 2020 Dec;46(12):2257-2261. doi: 10.1016/j.ejso.2020.07.003. Epub 2020 Jul 28.PMID: 32814680|
|2020||Outcomes from an international multicenter registry of patients with acute gastrointestinal bleeding undergoing endoscopic treatment with Hemospray.|
|Alzoubaidi D, Hussein M, Rusu R, Napier D, Dixon S, Rey JW, Steinheber C, Jameie-Oskooei S, Dahan M, Hayee B, Gulati S, Despott E, Murino A, Subramaniam S, Moreea S, Boger P, Hu M, Duarte P, Dunn J, Mainie I, McGoran J, Graham D, Anderson J, Bhandari P, Goetz M, Kiesslich R, Coron E, Lovat L, Haidry R.Dig Endosc. 2020 Jan;32(1):96-105. doi: 10.1111/den.13502. Epub 2019 Aug 30.PMID: 31365756|
|2020||Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study.|
|van Baar ACG, Holleman F, Crenier L, Haidry R, Magee C, Hopkins D, Rodriguez Grunert L, Galvao Neto M, Vignolo P, Hayee B, Mertens A, Bisschops R, Tijssen J, Nieuwdorp M, Guidone C, Costamagna G, Devière J, Bergman JJGHM.Gut. 2020 Feb;69(2):295-303. doi: 10.1136/gutjnl-2019-318349. Epub 2019 Jul 22.PMID: 31331994|
|2020||A case of dysphagia secondary to a double-lumen esophagus: endoscopic management with septotomy.|
|Rao R, Sweis R, Everson M, Plumb A, Haidry R.VideoGIE. 2020 Mar 3;5(3):98-101. doi: 10.1016/j.vgie.2019.11.015. eCollection 2020 Mar.PMID: 32154478 Free PMC article. No abstract available.|
|2020||Learning curves and the influence of procedural volume for the treatment of dysplastic Barrett’s esophagus.|
|Lipman G, Markar S, Gupta A; UK RFA Registry Working Group, Haidry RJ, Lovat LB.Gastrointest Endosc. 2020 Sep;92(3):543-550.e1. doi: 10.1016/j.gie.2020.02.041. Epub 2020 Mar 5.PMID: 32145288|
|2020||Intrapapillary capillary loop classification in magnification endoscopy: open dataset and baseline methodology.|
|García-Peraza-Herrera LC, Everson M, Lovat L, Wang HP, Wang WL, Haidry R, Stoyanov D, Ourselin S, Vercauteren T.Int J Comput Assist Radiol Surg. 2020 Apr;15(4):651-659. doi: 10.1007/s11548-020-02127-w. Epub 2020 Mar 12.PMID: 32166574 Free PMC article.|
|2020||Cryoballoon ablation for treatment of patients with refractory esophageal neoplasia after first line endoscopic eradication therapy.|
|Alzoubaidi D, Hussein M, Sehgal V, Makahamadze C, Magee CG, Everson M, Graham D, Sweis R, Banks M, Sami SS, Novelli M, Lovat L, Haidry R.Endosc Int Open. 2020 Jul;8(7):E891-E899. doi: 10.1055/a-1149-1414. Epub 2020 Jun 16.PMID: 32665972|
|2020||Hemostatic spray powder TC-325 in the primary endoscopic treatment of peptic ulcer related bleeding: multicentre international registry.|
|Hussein M, Alzoubaidi D, Fraile-López M, Weaver M, Ortiz-Fernández-Sordo’ J, Bassett P, Rey J, Hayee B, Despott E, Murino A, Moreea S, Boger P, Dunn J, Mainie I, Graham D, Mullady D, Early D, Ragunath K, Anderson J, Bhandari P, Goetz M, Kiesslich R, Coron E, Lovat L, Haidry R.Endoscopy. 2020 May 26. doi: 10.1055/a-1186-5360. Online ahead of print.PMID: 32459000|
|2020||Outcomes of Hemospray therapy in the treatment of intraprocedural upper gastrointestinal bleeding post-endoscopic therapy.|
|Hussein M, Alzoubaidi D, Serna A, Weaver M, Fernandez-Sordo JO, Rey JW, Hayee B, Despott E, Murino A, Moreea S, Boger P, Dunn J, Mainie I, Graham D, Mullady D, Early D, Ragunath K, Anderson J, Bhandari P, Goetz M, Kiesslich R, Coron E, de Santiago ER, Gonda T, Lovat LB, Haidry R.United European Gastroenterol J. 2020 Jun 26:2050640620938549. doi: 10.1177/2050640620938549. Online ahead of print.PMID: 32588788|
|2020||Risk factors for serious adverse events associated with multiband mucosectomy in Barrett’s esophagus: an international multicenter analysis of 3827 endoscopic resection procedures.|
|Belghazi K, Marcon N, Teshima C, Wang KK, Milano RV, Mostafavi N, Wallace MB, Kandel P, Mejía Pérez LK, Bourke MJ, Bahin F, Everson MA, Haidry R, Ginsberg GG, Ma GK, Koch AD, Ragunath K, Ortiz-Fernandez-Sordo J, di Pietro M, Seewald S, Weusten BL, Schoon EJ, Bisschops R, Bergman JJ, Pouw RE.Gastrointest Endosc. 2020 Aug;92(2):259-268.e2. doi: 10.1016/j.gie.2020.03.3842. Epub 2020 Mar 30.PMID: 32240684|
|2020||The cost-effectiveness of radiofrequency ablation for treating patients with gastric antral vascular ectasia refractory to first line endoscopic therapy.|
|Magee C, Graham D, Leonard C, McMaster J, Davies H, Skotchko M, Lovat L, Murray C, Mealing S, Smart H, Haidry R.Curr Med Res Opin. 2020 Jun;36(6):977-983. doi: 10.1080/03007995.2020.1747997. Epub 2020 Apr 14.|
|2020||Miniature gastrointestinal endoscopy: Now and the future.|
|McGoran JJ, McAlindon ME, Iyer PG, Seibel EJ, Haidry R, Lovat LB, Sami SS.World J Gastroenterol. 2019 Aug 14;25(30):4051-4060. doi: 10.3748/wjg.v25.i30.4051.PMID: 31435163 Free PMC article. Review.|
|2020||Deep sedation and anaesthesia in complex gastrointestinal endoscopy: a joint position statement endorsed by the British Society of Gastroenterology (BSG), Joint Advisory Group (JAG) and Royal College of Anaesthetists (RCoA).|
|Sidhu R, Turnbull D, Newton M, Thomas-Gibson S, Sanders DS, Hebbar S, Haidry RJ, Smith G, Webster G.Frontline Gastroenterol. 2019 Apr;10(2):141-147. doi: 10.1136/flgastro-2018-101145. Epub 2019 Jan 9.|
|2019||Duodenal mucosal resurfacing: proof-of-concept, procedural development, and initial implementation in the clinical setting.|
|Haidry RJ, van Baar AC, Galvao Neto MP, Rajagopalan H, Caplan J, Levin PS, Bergman JJ, Rodriguez L, Deviere J, Thompson CC.
Gastrointest Endosc. 2019 Mar 29. pii: S0016-5107(19)30215-9. doi: 10.1016/j.gie.2019.03.024.
|2019||Self-sizing radiofrequency ablation balloon for eradication of Barrett’s esophagus: results of an international multicenter randomized trial comparing 3 different treatment regimens.|
|Belghazi K, Pouw RE, Koch AD, Weusten BLAM, Schoon EJ, Curvers WL, Gotink AW, Mostafavi N, Haidry RJ, Pech O, Bergman JJGHM, Bisschops R.
Gastrointest Endosc. 2019 May 17. pii: S0016-5107(19)31715-8. doi: 10.1016/j.gie.2019.05.023. [Epub ahead of print]
|2019||Artificial intelligence for the real-time classification of intrapapillary capillary loop patterns in the endoscopic diagnosis of early oesophageal squamous cell carcinoma: A proof-of-concept study.|
|Everson M, Herrera L, Li W, Luengo IM, Ahmad O, Banks M, Magee C, Alzoubaidi D, Hsu HM, Graham D, Vercauteren T, Lovat L, Ourselin S, Kashin S, Wang HP, Wang WL, Haidry RJ.
United European Gastroenterol J. 2019 Mar;7(2):297-306. doi: 10.1177/2050640618821800
|2019||Radiofrequency ablation for patients with refractory symptomatic anaemia secondary to gastric antral vascular ectasia.|
|Magee C, Lipman G, Alzoubaidi D, Everson M, Sweis R, Banks M, Graham D, Gordon C, Lovat L, Murray C, Haidry R.
United European Gastroenterol J. 2019 Mar;7(2):217-224. doi: 10.1177/2050640618814659. Epub 2018 Nov 15.
|2019||Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett’s Esophagus-Related Neoplasia: A Feasibility Study.|
|Everson M, Magee C, Alzoubaidi D, Brogden S, Graham D, Lovat LB, Novelli M, Haidry R.
Dig Dis Sci. 2019 Apr 13. doi: 10.1007/s10620-019-05607-5. [
|2019||Comparison of two multiband mucosectomy devices for endoscopic resection of Barrett’s esophagus-related neoplasia.|
|Alzoubaidi D, Graham D, Bassett P, Magee C, Everson M, Banks M, Novelli M, Jansen M, Lovat LB, Haidry R.
Surg Endosc. 2019 Jan 22. doi: 10.1007/s00464-018-06655-0. [Epub ahead of print]
|2019||Achalasia diagnosed despite normal integrated relaxation pressure responds favorably to therapy.|
|Sanagapalli S, Roman S, Hastier A, Leong RW, Patel K, Raeburn A, Banks M, Haidry R, Lovat L, Graham D, Sami SS, Sweis R.
Neurogastroenterol Motil. 2019 Jun;31(6):e13586. doi: 10.1111/nmo.13586. Epub 2019 Apr
|2019||Dilation or biodegradable stent placement for recurrent benign esophageal strictures: a randomized controlled trial.|
|Walter D, van den Berg MW, Hirdes MM, Vleggaar FP, Repici A, Deprez PH, Viedma BL, Lovat LB, Weusten BL, Bisschops R, Haidry R, Ferrara E, Sanborn KJ, O’Leary EE, van Hooft JE, Siersema PD.
Endoscopy. 2018 Dec;50(12):C12. doi: 10.1055/a-0843-5973. Epub 2019 Feb 6.
|2019||Management of non-variceal upper gastrointestinal bleeding: where are we in|
|Alzoubaidi D, Lovat LB, Haidry R.
Frontline Gastroenterol. 2019 Jan;10(1):35-42. doi: 10.1136/flgastro-2017-100901. Epub 2018 Feb 9. Review.
|2018||A cost-effectiveness analysis of endoscopic eradication therapy (EET) for management of dysplasia arising in patients with Barrett’s esophagus in the United Kingdom.|
|Pollit V, Graham D, Leonard C, Filby A, McMaster J, Mealing SJ, Lovat LB, Haidry RJ.
Curr Med Res Opin. 2018 Nov 27:1-29. doi: 10.1080/03007995.2018.1552407. [Epub ahead of print]
|2018||Risk of lymph node metastases in patients with T1b oesophageal adenocarcinoma: A retrospective single centre experience.|
|Graham D, Sever N, Magee C, Waddingham W, Banks M, Sweis R, Al-Yousuf H, Mitchison M, Alzoubaidi D, Rodriguez-Justo M, Lovat L, Novelli M, Jansen M, Haidry R.
World J Gastroenterol. 2018 Nov 7;24(41):4698-4707. doi: 10.3748/wjg.v24.i41.4698.
|2018||Virtual chromoendoscopy by using optical enhancement improves the detection of Barrett’s esophagus-associated neoplasia.|
|Everson MA, Lovat LB, Graham DG, Bassett P, Magee C, Alzoubaidi D, Fernández-Sordo JO, Sweis R, Banks MR, Wani S, Esteban JM, Ragunath K, Bisschops R, Haidry RJ.
Gastrointest Endosc. 2018 Oct 3. pii: S0016-5107(18)33144-4. doi: 10.1016/j.gie.2018.09.032. [Epub ahead of
|2018||Machine Learning Creates a Simple Endoscopic Classification System that Improves Dysplasia Detection in Barrett’s Oesophagus amongst Non-expert Endoscopists.|
|Sehgal V, Rosenfeld A, Graham DG, Lipman G, Bisschops R, Ragunath K, Rodriguez-Justo M, Novelli M, Banks MR, Haidry RJ, Lovat LB.
Gastroenterol Res Pract. 2018 Aug 29;2018:1872437. doi: 10.1155/2018/1872437. eCollection 2018.
|2018||A prospective multicenter study using a new multiband mucosectomy device for endoscopic resection of early neoplasia in Barrett’s esophagus.|
|Pouw RE, Beyna T, Belghazi K, Koch AD, Schoon EJ, Haidry R, Weusten BL, Bisschops R, Shaheen NJ, Wallace MB, Marcon N, Heise-Ginsburg R, Gotink AW, Wang KK, Leggett CL, Ortiz-Fernández-Sordo J, Ragunath K, DiPietro M, Pech O, Neuhaus H, Bergman JJ.
Gastrointest Endosc. 2018 Oct;88(4):647-654. doi: 10.1016/j.gie.2018.06.030. Epub 2018 Jul 6.
|2018||A Survey of Expert Practice and Attitudes Regarding Advanced Imaging Modalities in Surveillance of Barrett’s Esophagus.|
|Machicado JD, Han S, Yadlapati RH, Simon VC, Qumseya BJ, Sultan S, Kushnir VM, Komanduri S, Rastogi A, Muthusamy VR, Haidry R, Ragunath K, Singh R, Hammad HT, Shaheen NJ, Wani S.
Dig Dis Sci. 2018 Sep 3. doi: 10.1007/s10620-018-5257-3. [Epub ahead of print]
|2018||Detection and characterization of colorectal polyps using high-definition white light and i-Scan: Evidence-based consensus recommendations using a modified Delphi process.|
|Bhandari P, Thayalasekaran S, Keisslich R, Bisschops R, Hoffmann A, Haidry R, Esteban J, López Viedma B, Godzhello E, Almadi M, Neumann H, Sanduleanu S.
United European Gastroenterol J. 2018 Jun;6(5):748-754. doi: 10.1177/2050640618764531. Epub 2018 Mar 27.
|2018||Radiofrequency ablation compared with argon plasma coagulation after endoscopic resection of high-grade dysplasia or T1 adenocarcinoma in Barrett’s esophagus: a randomized pilot study (BRIDE).|
|Peerally MF, Bhandari P, Ragunath K, Barr H, Haidry R, Lovat L, Smart H, Harrison R, Stokes C, Smith K, Morris T, de Caestecker JS.
Gastrointest Endosc. 2018 Aug 1. pii: S0016-5107(18)32898-0. doi: 10.1016/j.gie.2018.07.031. [Epub ahead of print]
|2018||Endoscopic ablation for esophageal early squamous cell neoplasia – can we predict success and recurrence?|
Endoscopy. 2018 Aug;50(8):739-740. doi: 10.1055/a-0629-7959. Epub 2018 Jul 26.
|2018||Focal cryoballoon versus radiofrequency ablation of dysplastic Barrett’s esophagus: impact on treatment response and postprocedural pain.|
|van Munster SN, Overwater A, Haidry R, Bisschops R, Bergman JJGHM, Weusten BLAM.
Gastrointest Endosc. 2018 Jun 19. pii: S0016-5107(18)32769-X. doi: 10.1016/j.gie.2018.06.015.
|2018||Dilation or biodegradable stent placement for recurrent benign esophageal strictures: a randomized controlled trial.|
|Walter D, van den Berg MW, Hirdes MM, Vleggaar FP, Repici A, Deprez PH, Viedma BL, Lovat LB, Weusten BL, Bisschops R, Haidry R, Ferrara E, Sanborn KJ, O’Leary EE, van Hooft JE, Siersema PD.
Endoscopy. 2018 Jun 8. doi: 10.1055/a-0602-4169. [Epub ahead of print]
|2018||Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression.|
|Pye H, Butt MA, Funnell L, Reinert HW, Puccio I, Rehman Khan SU, Saouros S, Marklew JS, Stamati I, Qurashi M, Haidry R, Sehgal V, Oukrif D, Gandy M, Whitaker HC, Rodriguez-Justo M, Novelli M, Hamoudi R, Yahioglu G, Deonarain MP, Lovat LB.
Oncotarget. 2018 May 1;9(33):22945-22959. doi: 10.18632/oncotarget.25159. eCollection 2018 May 1.
|2018||Can the depth of invasion of early esophageal cancer be predicted based on endoscopic evidence?|
|Maes S, Haidry R, Bisschops R.
Minerva Chir. 2018 Aug;73(4):385-393. doi: 10.23736/S0026-4733.18.07760-X. Epub 2018 May 24.
|2018||UK guidelines on oesophageal dilatation in clinical practice.|
|Sami SS, Haboubi HN, Ang Y, Boger P, Bhandari P, de Caestecker J, Griffiths H, Haidry R, Laasch HU, Patel P, Paterson S, Ragunath K, Watson P, Siersema PD, Attwood SE.
Gut. 2018 Feb 24. pii: gutjnl-2017-315414. doi: 10.1136/gutjnl-2017-315414.
|2018||How to Perform a High-Quality Examination in Patients With Barrett’s Esophagus.|
|Everson MA, Ragunath K, Bhandari P, Lovat L, Haidry R.
Gastroenterology. 2018 Apr;154(5):1222-1226. doi: 10.1053/j.gastro.2018.03.001. Epub 2018 Mar 3.
|2018||Impaired motility in Barrett’s esophagus: A study using high-resolution manometry with physiologic challenge.|
|Sanagapalli S, Emmanuel A, Leong R, Kerr S, Lovat L, Haidry R, Banks M, Graham D, Raeburn A, Zarate-Lopez N, Sweis R.
Neurogastroenterol Motil. 2018 Mar 15. doi: 10.1111/nmo.13330.
|2018||Development of Evidence Based Surveillance Intervals following Radiofrequency Ablation of Barrett’s Esophagus.|
|Cotton CC, Haidry R, Thrift AP, Lovat L, Shaheen NJ.
Gastroenterology. 2018 Apr 12. pii: S0016-5085
|2017||Long-term outcomes of the randomized controlled trial comparing 5-aminolaevulinic acid and Photofrin photodynamic therapy for Barrett’s oesophagus related neoplasia.|
|Kohoutova D, Haidry R, Banks M, Butt MA, Dunn J, Thorpe S, Lovat L.
Scand J Gastroenterol. 2017 Nov 21:1-6. doi: 10.1080/00365521.2017.1403646.
|2017||Systematic assessment with I-SCAN magnification endoscopy and acetic acid improves dysplasia detection in patients with Barrett’s esophagus.|
|Lipman G, Bisschops R, Sehgal V, Ortiz-Fernández-Sordo J, Sweis R, Esteban JM, Hamoudi R, Banks MR, Ragunath K, Lovat LB, Haidry RJ.
Endoscopy. 2017 Dec;49(12):1219-1228. doi: 10.1055/s-0043-113441.
|2017||Endoscopic management of Barrett’s and early oesophageal neoplasia.|
|Lipman G, Haidry RJ.
Frontline Gastroenterol. 2017 Apr;8(2):138-142. doi: 10.1136/flgastro-2016-100763. Epub 2017 Feb 10. Review.
|2017||Cost-effectiveness analysis of endoscopic eradication therapy for treatment of high-grade dysplasia in Barrett’s esophagus.|
|Filby A, Taylor M, Lipman G, Lovat L, Haidry R.
J Comp Eff Res. 2017 May 25. doi: 10.2217/cer-2016-0089. [Epub ahead of print]
|2017||Risk stratification of Barrett’s oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study.|
|Ross-Innes CS, Chettouh H, Achilleos A, Galeano-Dalmau N, Debiram-Beecham I, MacRae S, Fessas P, Walker E, Varghese S, Evan T, Lao-Sirieix PS, O’Donovan M, Malhotra S, Novelli M, Disep B, Kaye PV, Lovat LB, Haidry R, Griffin M, Ragunath K, Bhandari P, Haycock A, Morris D, Attwood S, Dhar A, Rees C, Rutter MD, Ostler R, Aigret B, Sasieni PD, Fitzgerald RC; BEST2 study group..
Lancet Gastroenterol Hepatol. 2017 Jan;2(1):23-31. doi: 10.1016/S2468-1253(16)30118-2. Epub 2016 Nov 11.
|2017||Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate.|
|Butt MA, Pye H, Haidry RJ, Oukrif D, Khan SU, Puccio I, Gandy M, Reinert HW, Bloom E, Rashid M, Yahioglu G, Deonarain MP, Hamoudi R, Rodriguez-Justo M, Novelli MR, Lovat LB.
Oncotarget. 2017 Feb 15. doi: 10.18632/oncotarget.15340.
|2016||Role of body composition and metabolic profile in Barrett’s oesophagus and progression to cancer.|
|Di Caro S, Cheung WH, Fini L, Keane MG, Theis B, Haidry R et al.
Eur J Gastroenterol Hepatol. 2015 Dec 14.
|2015||Esophageal neoplasia arising from subsquamous buried glands after an apparently successful photodynamic therapy or radiofrequency ablation for Barrett’s associated neoplasia.|
|Kohoutova D, Haidry R, Banks M, Bown S, Sehgal V, Butt MA, Graham D, Thorpe S, Novelli M, Rodriguez-Justo M, Lovat L.
Scand J Gastroenterol. 2015 Nov;50(11):1315-21. doi: 10.3109/00365521.2015.1043578. Epub 2015 May 8.
|2015||Long-term durability of radiofrequency ablation for Barrett’s-related neoplasia.|
|Haidry R, Lovat L.
Curr Opin Gastroenterol. 2015 Jul;31(4):316-20.
|2015||Comparing outcome of radiofrequency ablation in Barrett’s with high grade dysplasia and intramucosal carcinoma: a prospective multicenter UK registry.|
|Haidry RJ et al.
Endoscopy. 2015 Jun 30. [Epub ahead of print]
|2015||Radiofrequency Ablation for Barrett’s Dysplasia: Past, Present and the Future?
Haidry R, Lovat L, Sharma P.
|Curr Gastroenterol Rep. 2015 Mar;17(3):433. doi: 10.1007/s11894-015-0433-5|
|2015||Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett’s oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry
Haidry et al.
|2015||Primary malignant melanoma of the esophagus.|
|Wallis G, Sehgal V, Haider A, Bridgewater J, Novelli M, Dawas K, Haidry R. Endoscopy. 2015;47 Suppl 1 UCTN:E81-2. doi: 10.1055/s-0034-1391126. Epub 2015 Feb 17|
|2015||Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: a multi-center case-control study.|
|Ross-Innes CS, Debiram-Beecham I, O’Donovan M, Walker E, Varghese S, Lao-Sirieix P, Lovat L, Griffin M, Ragunath K, Haidry R, Sami SS, Kaye P, Novelli M, Disep B, Ostler R, Aigret B, North BV, Bhandari P, Haycock A, Morris D, Attwood S, Dhar A, Rees C, Rutter MD, Sasieni PD, Fitzgerald RC; BEST2 Study Group.
PLoS Med. 2015 Jan 29;12(1):e1001780. doi: 10.1371/journal.pmed.1001780. 2015 Jan.
|2014||Squamous cell carcinoma after radiofrequency ablation for Barrett’s dysplasia.
Zeki SS, Haidry Ret al.
|World J Gastroenterol. 2014 Apr 21;20(15):4453-6. doi: 1 0.3748/wjg.v20.i15.4453.|
|2013||Clonal Selection and Persistence in Dysplastic Barrett’s Esophagus and Intramucosal Cancers After Failed Radiofrequency Ablation.|
|Zeki SS, Haidry R,Graham TA, Rodriguez-Justo M, Novelli M, Hoare J, Dunn J, Wright NA, Lovat LB, McDonald SA.
Am J Gastroenterol. 2013 Aug 13. doi: 10.1038/ajg.2013.238
|2013||Radiofrequency Ablation For Esophageal Squamous High Grade Dysplasia And Early Squamous Cell Carcinoma: Outcomes From The United Kingdom Halo Radiofrequency Ablation National Registry|
|Haidry Rehan ,Dunn Jason, Butt Mohammned, Banks Matthew, Gupta Abhinav, Smart Howard, Bhandari Pradeep, Smith Lesley Ann, Willert Robert, Fullarton Grant, John Morris, Di Pietro Massimo, Penman Ian, Novelli Marco, Lovat Laurence
World J Gastroenterol. 2013 September 28; 19(36): 6011-6019.
|2013||Radiofrequency Ablation and Endoscopic Mucosal Resection for Dysplastic Barrett’s Esophagus and Early Esophageal Adenocarcinoma: Outcomes of the UK National Halo RFA Registry|
|Rehan J. Haidry, Jason M. Dunn, Mohammed A. Butt, Matthew G. Burnell, et al.
|2013||Squamous cell cancer after radiofrequency ablation for Barrett’s dysplasia|
|Sebastian S. Zeki, Rehan Haidry, Manuel Justo-Rodriguez, Laurence B. Lovat, Nicholas A. Wright, Stuart A. McDonald
World J Gastroenterol. 2014 April 21; 20(15): 4453-4456.
|2013||A randomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in Barrett’s oesophagus.|
|Dunn JM, Mackenzie GD, Banks MR, Mosse CA, Haidry R, Green S, Thorpe S, Rodriguez-Justo M, Winstanley A, Novelli MR, Bown SG, Lovat LB.
Lasers Med Sci. 2012 Jun 15.
|2011||Polyp detection is improved by megapixel white light high resolution Colonoscopy in the UK National Bowel cancer screening program.|
|Matthew R Banks, Rehan J Haidry,Lisa Whitley, Judith Stein, Louise Langmead, Stuart L Bloom, Austin O’Bichere, Sara McCartney, Kalpesh Basherdas,Manuel Rodriguez-Justo, Laurence B Lovat World Journal Gastroenterology: Ms No: wjg/2011/02873|
|2011||Advances in Diagnostic Endoscopy|
|Haidry R, Butt A, Lovat L: Medicine, Volume 39, issue 5, Pages 279-283 (May 2011)|
|2012||Medical Imaging In Clinical Practice, ISBN 980-953-307-710-4|
|Chapter 12 – Gastrointestinal Endoscopy|
|2012||Gastrointestinal Endoscopy in the Cancer Patient, Fourth Edition. Edited by John Deutsch and Matthew R. Banks. 2013 John Wiley & Sons, Ltd. Published 2013 by Blackwell Publishing Ltd.|
– Chapter 3 – Endoscopic Management of Premalignant and Early Malignant Diseases of the Esophagus
To make an enquiry or to book an appointment please call Dr. Haidry’s secretary on: 020 7183 7965